prevention of relapses and disability by interferon beta-1a

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

The Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) was a double-blind, placebo-controlled trial of interferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Patients had mild to moderate multiple sclerosis (EDSS scores 0 - 5.0).

Patients were randomised to 2 years of:

  • placebo
  • 22 mcg subcutaneously three times per week
  • 44 mcg subcutaneously three times pre week

Reference:

  • 1) PRISMS Study Group. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352(7), 1498-504

Last reviewed 01/2018

Links: